Mechanistically, we found that VII can bind to RORα, enhance its protein stability, and inhibit the FAK/AKT/GSK3β signaling pathway in ovarian cancer cells resistant to PARP inhibitors through the RORα/ECM1/VEGFR2 signaling axis. Here, AKT1 is linked to ovarian cancer.